Israel OKs use of generic AbbVie drug to treat coronavirus despite patent [Reuters (UK)]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Reuters
Israel OKs use of generic AbbVie drug to treat coronavirus despite patent - Reuters 2 Min Read TEL AVIV (Reuters) - Israel’s attorney general on Thursday approved for the first time the use of a generic version of a patent-protected drug to treat coronavirus patients. The anti-viral drug Kaletra, produced by AbbVie Inc, is a treatment for HIV but Israel’s Health Ministry found it could be a possible treatment for COVID-19 and a preliminary permit for the drug was issued. There are 529 confirmed coronavirus cases in Israel. AbbVie’s patent for Kaletra in Israel ends in 2024 but the patent in some other countries, such as India, has expired. “The company with the patent and the official importer in Israel are not able to supply the necessary inventory for this drug, which is very much in demand all over the world these days,” the Justice Ministry said. “Therefore ... the state will be able to import generic substitutes from countries where the patent has expired.” It said generic Kaletr
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- AbbVie Inc. (NYSE: ABBV) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $206.00 price target on the stock.MarketBeat
- Antibody Drug Conjugates Contract Manufacturing Market Analysis and Forecast (2025-2030) by Linker, Condition, End Use and Region - Industry Set to Experience 11.8% CAGR Over the Forecast Period [Yahoo! Finance]Yahoo! Finance
- AbbVie Insiders Sold US$56m Of Shares Suggesting Hesitancy [Yahoo! Finance]Yahoo! Finance
- Specialty Pharmaceuticals Research Report: Increased Reimbursement Through Medical and Pharmacy Benefits Driving the Market, Reaching $965 Billion by 2030 [Yahoo! Finance]Yahoo! Finance
- Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? [Yahoo! Finance]Yahoo! Finance
ABBV
Earnings
- 10/30/24 - Beat
ABBV
Sec Filings
- 11/4/24 - Form S-8
- 11/4/24 - Form S-8
- 11/4/24 - Form 10-Q
- ABBV's page on the SEC website